Sulfated glycosaminoglycans in equine joint diseases

Compendium on Continuing Education for the Practicing Veterinarian

Volumn 19, Issue 11, 1997, Pages 1292-1295

  Trotter, Gayle W ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EQUIDAE; EQUUS CABALLUS;

EID: 0031312543     PISSN: 01931903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Caron JP, Kaneene JB, Miller R: Results of a survey of equine practitioners on the use and perceived efficacy of polysulfated glycosaminoglycan. JAVMA 209:1564-1568, 1996.
2. Jones EW, White G: The current status of the clinical use of polysulfated glycosaminoglycan in the USA. J Equine Vet Sci 16:53-57, 1996.
3. Trotter GW: Polysulfated glycosaminoglycan (Adequan®), in McIlwraith CW, Trotter GW (eds): Joint Disease in the Horse. Philadelphia, WB Saunders Co, 1996, pp 270-280.
4. Little C, Ghosh P: Potential use of pentosan polysulfate for the treatment of equine joint disease, in McIlwraith CW, Trotter GW (eds): Joint Disease in the Horse. Philadelphia, WB Saunders Co, 1996, pp 281-292.
5. Lequesne M, Brandt K, Bellamy N, et al: Guidelines for testing slow-acting drugs in osteoarthritis. J Rheumatol 21 (Suppl 41):65-73, 1994.
6. 3H-PSGAG concentration in the synovial fluid of the equine antebrachial, metacarpophalangeal, coronopedal and tibiotarsal joints following a 500-mg IM injection. J Equine Vet Sci 15:274-278, 1995.
7. Todhunter R, Freeman K, Yeager AE: Effects of exercise and polysulfated glycosaminoglycan on the development of osteoarthritis in equine carpal joints with osteochondral defects. Vet Surg 22:330-342, 1993.
8. McIlwraith CW: Joint lameness. Proc AAEP 42:108-111, 1996.
9. Crisman M, Furr M, Ley W, et al: Evaluation of polysulfated glycosaminoglycan for the treatment of navicular disease: A double blind study. Proc AAEP 39:219-220, 1993.
10. Reichelt A, Forster K, Fischer M, et al: Efficacy and safety of intramuscular glucosamine sulfate in osteoarthritis of the knee. Arzneimittelforschung 44:75-80, 1994.
11. Conte A, Volpi N, Palmiera L, et al: Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneimitteforschung 45:918-925, 1995.
12. Bassleer C, Henrotin Y, Franchimont P: In vitro evaluation of drugs proposed as chondroprotective agents. Int J Tissue React 14:231-241, 1992.
13. White G, Jones EW, Hamm J, Sanders T: The efficacy of orally administered sulfated glycosaminoglycan in chemically induced equine synovitis and degenerative joint disease. J Equine Vet Sci 14:350-353, 1994.
14. Hanson R: Oral glycosaminoglycans in treatment of degenerative joint disease in horses. Equine Prac 18:18-22, 1996.